Brain-derived neurotrophic factor precursor in the immune system is a novel target for treating multiple sclerosis

• Published in: Theranostics Vol. 11; no. 2; pp. 715 - 730
• Main Authors: Hu, Zhao-Lan, Luo, Cong, Hurtado, Plinio Reinaldo, Li, Hui, Wang, Shuang, Hu, Bo, Xu, Jun-Mei, Liu, Yang, Feng, Shi-Qing, Hurtado-Perez, Ernesto, Chen, Kang, Zhou, Xin-Fu, Li, Chang-Qi, Dai, Ru-Ping
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 01.01.2021; Ivyspring International Publisher
• Subjects: Ataxia; Biotechnology industry; Brain-derived neurotrophic factor; Disease; Immune system; Laboratories; Lymphocytes; Monoclonal antibodies; Multiple sclerosis; Nervous system; Pathogenesis; Proteins; Research Paper; Sheep; Spinal cord; United States > US; China; B cell; Multiple sclerosis; immune response; immunotherapy; antibodies; proBDNF; brain-derived neurotrophic factor
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.51390

Brain-derived neurotrophic factor precursor (proBDNF) is expressed in the central nervous system (CNS) and the immune system. However, the role of proBDNF in the pathogenesis of multiple sclerosis (MS) is unknown. Peripheral blood and post-mortem brain and spinal cord specimens were obtained from multiple sclerosis patients to analyze proBDNF expression in peripheral lymphocytes and infiltrating immune cells in the lesion site. The proBDNF expression profile was also examined in the experimental autoimmune encephalomyelitis (EAE) mouse model, and polyclonal and monoclonal anti-proBDNF antibodies were used to explore their therapeutic effect in EAE. Finally, the role of proBDNF in the inflammatory immune activity of peripheral blood mononuclear cells (PBMCs) was verified experiments. High proBDNF expression was detected in the circulating lymphocytes and infiltrated inflammatory cells at the lesion sites of the brain and spinal cord in MS patients. In the EAE mouse model, proBDNF was upregulated in CNS and in circulating and splenic lymphocytes. Systemic but not intracranial administration of anti-proBDNF blocking antibodies attenuated clinical scores, limited demyelination, and inhibited proinflammatory cytokines in EAE mice. Immuno-stimulants treatment increased the proBDNF release and upregulated the expression of p75 neurotrophic receptors (p75 ) in lymphocytes. The monoclonal antibody against proBDNF inhibited the inflammatory response of PBMCs upon stimulations. The findings suggest that proBDNF from immune cells promotes the immunopathogenesis of MS. Monoclonal Ab-proB may be a promising therapeutic agent for treating MS.